Back to News
Market Impact: 0.25
MAIA Doses First U.S. Patient In Phase 2 THIO-101 Trial For Advanced Non-Small Cell Lung Cancer
Source: Nasdaq
Healthcare & Biotech
MAIA Biotechnology dosed the first U.S. patient in its ongoing Phase 2 THIO-101 trial of Ateganosine for third-line non-small cell lung cancer. The milestone advances clinical development of the company’s telomere-targeting lead candidate, but no efficacy or safety data were reported.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
MAIA0.65
More News
- Premarket movers: Intel jumps on SK Hynix memory-chip talks, J.B. Hunt slides
- Japan has a problematic age gap: 100,000-plus residents are over 100 and the pension system is buckling
- The MLB and its Dominican pipeline is selling false promises and shady contracts to children as young as 11
- Arrowhead Pharmaceuticals at H.C. Wainwright: launch and pipeline widen
- A healthcare provider is set up for a big move higher, according to the charts
- The Download: AI’s trillion-dollar gamble and OpenAI’s biology data bid
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- The Great Divergence: North American Banking at the Crossroads of Monetary Policy and Agentic AI (Q4 2025 Bank Earnings)
- AI for M&A Target Screening: From Universe to Deal File